Update on Alzheimer's disease therapeutics

Area of Science:

• Neurology
• Pharmacology
• Biochemistry

Background:

• Alzheimer's disease (AD) is the primary cause of dementia globally, marked by cognitive decline and neuropsychiatric symptoms.
• Despite numerous drug candidates in clinical trials, none have successfully slowed AD progression, highlighting the need for new therapeutic strategies.
• The field is shifting towards earlier disease identification and intervention, potentially addressing past clinical trial failures.

Purpose of the Study:

• To review recent findings in Alzheimer's disease therapeutics.
• To discuss emerging drug candidates and their mechanisms of action.
• To explore novel therapeutic interventions beyond established pathways.

Main Methods:

• Review of clinical and preclinical studies on Alzheimer's disease drug candidates.
• Analysis of therapeutic strategies targeting amyloid-beta (Aβ) production, aggregation, and clearance.
• Examination of treatments focused on preventing tau protein phosphorylation.
• Inclusion of 'other therapies' addressing underlying AD pathology.

Main Results:

• Several therapeutic approaches are under active development, including secretase inhibitors for Aβ production.
• Strategies to reduce Aβ plaque burden through aggregation inhibition or disruption are being investigated.
• Active and passive immunotherapies aim to enhance Aβ clearance from the brain.
• Interventions targeting tau protein phosphorylation represent another key area of research.
• A category of 'other therapies' encompasses treatments with rational interventions for AD pathology.

Conclusions:

• Current Alzheimer's disease drug development focuses on multiple mechanisms, including Aβ and tau pathways.
• Earlier intervention strategies are crucial for improving the efficacy of Alzheimer's disease treatments.
• Continued research into diverse therapeutic avenues is essential for combating Alzheimer's disease progression.